Month: September 2019

RPM International Inc. RPM is scheduled to report first-quarter fiscal 2020 results on Oct 2, before the opening bell. In fiscal fourth-quarter 2019, the company’s earnings topped the Zacks Consensus Estimate by 8.8% but revenues missed the same by 0.2% […]

The U.S. Energy Department's weekly inventory release showed a larger-than-expected increase in natural gas supplies. The bearish injection, which was also higher than the five-year average, sparked a sell-off that left the U.S […]

Pfizer Inc. PFE announced that its investigational oral JAK1 inhibitor abrocitinib has met all co-primary and key secondary endpoints in the second pivotal phase III study (B7451013). The candidate is being evaluated as a monotherapy for the treatment of moderate-to-severe atopic dermatitis (AD) also known as eczema in patients aged 12 years and above […]

Apple AAPL is reportedly planning to release films at theaters first and give them a wider window to run (by weeks) before bringing them to its upcoming streaming service, Apple TV+. Per The Wall Street Journal, the iPhone-maker is already discussing plans with executives from the theater industry. […]

Choice Hotels International, Inc. CHH continues to expand through franchise agreements. […]

After opening the first community — Falling Water in Bonney Lake — in the Seattle area, KB Home KBH has plans to open its second and third new-home communities, thereby expanding presence in the Pacific Northwest region. These new-home communities, namely Cascade Vista in Spanaway and Ridgecrest in Kent, will give buyers the ability to personalize their homes from homesites and floor plans to design features. […]

AstraZeneca AZN presented detailed data from a phase III study evaluating the company’s and Merck’s MRK PARP inhibitor, Lynparza, for a broader advanced ovarian cancer patient population at the European Society of Medical Oncology (ESMO) congress in Barcelona, Spain The PAOLA-1 study evaluated Lynpazra as a first-line maintenance treatment in combination with Roche’s RHHBY Avastin (bevacizumab) versus Avastin alone in women suffering from advanced ovarian cancer regardless of their biomarker status or surgical outcome. Data from the study showed that Lynparza improved progression-free-survival (PFS), or the time the abovementioned women lived without disease progression, to a median of 22.1 months versus 16.6 months in the Avastin arm in the broad population. Lynparza added to bevacizumab reduced the risk of disease progression or death by 41% in the overall patient population. […]

Arthur J. Gallagher & Co. AJG recently agreed to buy LSG Insurance Partners. […]

Recalls are rampant in the auto industry across the globe and a steep rise has been noticed in recent years, according to the National Highway Traffic Safety Administration. Frequent recalls not only result in significant financial expenses and lower vehicle resale value, but also involve reputational costs. Recalls on the Rise: Here’s Why With cars becoming more high tech than ever, recalls have been rising […]

GlaxoSmithKline plc GSK presented positive detailed data from the phase III PRIMA study evaluating its PARP inhibitor, Zejula (niraparib), as monotherapy for maintenance therapy of women with first-line ovarian cancer who have received platinum-based chemotherapy. Data demonstrated that Zejula, when given as monotherapy, significantly reduced the risk of disease progression or death by 38%, irrespective of biomarker status. […]

Voya Financial ’s VOYA shares have surged 36.4% year to date, outperforming the industry 's growth of 17% and the Zacks S&P 500 composite’s rise of 16.8%. Solid segmental performance, cost saving initiatives, strong capital position and prudent capital deployment should continue to drive the stock. […]

Value investing is easily one of the most popular ways to find great stocks in any market environment. After all, who wouldn’t want to find stocks that are either flying under the radar and are compelling buys, or offer up tantalizing discounts when compared to fair value? […]

MoneyGram International, Inc. MGI , a leading global money transfer company, has announced a partnership with Agricultural Bank of Egypt (ABE), one of the biggest agricultural banks in Arabian countries and the Middle East. Per the pact, MoneyGram will provide money transfer services at the bank's 1,210 branches throughout the country. […]